4/22
02:11 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
4/22
07:50 am
kura
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]
Low
Report
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML [Yahoo! Finance]
4/22
07:30 am
kura
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
Low
Report
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
4/15
11:03 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/10
07:39 am
kura
Kura Oncology to Participate in Stifel Targeted Oncology Forum [Yahoo! Finance]
Medium
Report
Kura Oncology to Participate in Stifel Targeted Oncology Forum [Yahoo! Finance]
4/10
07:30 am
kura
Kura Oncology to Participate in Stifel Targeted Oncology Forum
Medium
Report
Kura Oncology to Participate in Stifel Targeted Oncology Forum
4/5
07:30 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Neutral
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
4/3
11:01 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
3/6
12:35 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Low
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
3/6
07:38 am
kura
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma [Yahoo! Finance]
Medium
Report
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma [Yahoo! Finance]
3/6
07:30 am
kura
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
Medium
Report
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
3/1
05:00 pm
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Medium
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2/28
02:29 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $32.00 price target on the stock.
2/28
10:12 am
kura
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Low
Report
Kura Oncology, Inc. (NASDAQ:KURA) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
2/28
08:17 am
kura
Kura Oncology, Inc. (NASDAQ: KURA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) had its "outperform" rating re-affirmed by analysts at Wedbush. They now have a $37.00 price target on the stock.
2/27
05:02 pm
kura
Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Kura Oncology Inc (KURA) Reports Q4 and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
04:10 pm
kura
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]
2/27
04:01 pm
kura
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
2/26
07:45 am
kura
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia [Yahoo! Finance]
Low
Report
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia [Yahoo! Finance]
2/26
07:30 am
kura
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
Low
Report
Kura Oncology Doses First Patient in KOMET-008 Trial of Ziftomenib in Combination with Standards of Care, Including FLT3 Inhibitor, in Acute Myeloid Leukemia
2/22
07:30 am
kura
Kura Oncology to Participate in Three Upcoming Investor Conferences
Low
Report
Kura Oncology to Participate in Three Upcoming Investor Conferences
2/20
07:30 am
kura
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
Low
Report
Kura Oncology to Report Fourth Quarter and Full Year 2023 Financial Results
2/12
10:06 pm
kura
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Kura Oncology, Inc. (NASDAQ: KURA) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
2/2
07:40 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
Low
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) [Yahoo! Finance]
2/2
07:30 am
kura
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Low
Report
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)